[Is it cost-benefit acceptable the change of EPO subcutaneous to intravenous administration in patients in hemodialysis?].
Peces
R
R
D003362:Cost-Benefit Analysis; D004921:Erythropoietin / Q000008:administration & dosage / Q000191:economics*; D006801:Humans; D007275:Injections, Intravenous / Q000191:economics; D007279:Injections, Subcutaneous / Q000191:economics
D004921:Erythropoietin